BioCryst Pharmaceuticals Inc. (BCRX) shares surged 4.38% in after-hours on Tuesday, January 11, 2022, and closed the daily trading at $17.15. Even in the regular trading session of Tuesday, BCRX’s stock gained 11.16%. BCRX shares have risen 104.35% over the last 12 months, and they have moved up 19.75% in the past week. Over the past three months, the stock has gained 11.69%, while over the past six months, it has gained 5.12%.
Let’s have a brief look at its recent news and developments.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
>> 7 Top Picks for the Post-Pandemic Economy <<
BCRX latest news
On January 10, 2022, BioCryst Pharmaceuticals, Inc. (BCRX) announced preliminary, unaudited ORLADEYO® (berotralstat) revenue for the fourth quarter and full-year 2021 and provided new guidance for full-year 2022 ORLADEYO net revenue and expected peak ORLADEYO sales.
Read More
Updates about ORLADEYO
BCRX reported preliminary unaudited ORLADEYO net revenue of $45.6 million for the fourth quarter of 2021. For the full year of 2021, the revenue was $122 million.
ORLADEYO prescriber base continues to grow significantly and it is now covered by all major payors and national and regional pharmacy benefit managers, which will lead to more patients being reimbursed quickly.
BioCryst is expecting that ORLADEYO will become their most prescribed prophylactic treatment in the next 12 months and revenues in 2022 to more than double in the second year of launch as the company benefits from a full year of reimbursement and continued strong demand from patients and physicians.
BCRX commenced enrolling BCX9930 Pivotal Trials
BioCryst is currently enrolling patients in two global pivotal trials, REDEEM-1, and REDEEM-2, with the company’s oral Factor D inhibitor, BCX9930 (500 mg bid), in patients with paroxysmal nocturnal hemoglobinuria (PNH).
The company enrolled its first patient on January 07, 2022, and The U.S. Food and Drug Administration has granted both Fast Track status and Orphan Drug Designation to BCX9930 for PNH.
BCRX participation in the recent event
BioCryst Pharmaceuticals, Inc. (BCRX) recently participated in the 40th Annual J.P. Morgan Healthcare Conference, which was held virtually on Monday, January 10, 2022.
BCRX inducement grants
On January 04, 2022, the Board of Directors of BioCryst Pharmaceuticals, Inc. (BCRX) granted 11 newly-hired employees inducement options to purchase an aggregate of 91,000 shares of BioCryst common stock as inducements material to each employee entering into employment with BioCryst. The options were granted under Nasdaq Listing Rule 5635(c)(4).
>> 7 Top Picks for the Post-Pandemic Economy <<
Conclusion
BioCryst stock shined on Tuesday after the company reported top-notch financial figures for Q4 and FY 2021. We can expect it to continue to climb up in the coming trading sessions on Wednesday as well.